Univariate analysis of DFS probability in the 450 patients with malignant disease
| . | Univariate analysis . | ||||
|---|---|---|---|---|---|
| No. of cases . | Events . | Probability, % . | (95% CI) . | P . | |
| Patient age | |||||
| Younger than 5 y | 110 | 35 | 66 | (56 -76) | NS |
| 5-10 y | 174 | 72 | 57 | (49 -64) | |
| 10-15 y | 125 | 52 | 57 | (48 -66) | |
| 15 y or older | 41 | 17 | 54 | (35 -72) | |
| Donor age | |||||
| Younger than 5 y | 81 | 31 | 61 | (50 -72) | .09 |
| 5-0 y | 95 | 31 | 65 | (55 -76) | |
| 10-15 y | 64 | 22 | 63 | (49 -76) | |
| 15-20 y | 55 | 18 | 65 | (52 -78) | |
| 20-30 y | 69 | 32 | 52 | (40 -64) | |
| 30-40 y | 56 | 24 | 48 | (34 -62) | |
| 40 y or older | 30 | 14 | 45 | (21 -70) | |
| Sex | |||||
| Female donor and male recipient | 103 | 53 | 59 | (50 -67) | NS |
| Other | 320 | 123 | 59 | (53 -65) | |
| Diagnosis | |||||
| ALL | 268 | 116 | 56 | (50 -62) | NS |
| AML | 99 | 30 | 64 | (53 -76) | |
| MDS | 36 | 15 | 54 | (35 -73) | |
| CML | 28 | 8 | 66 | (45 -87) | |
| Lymphoma | 19 | 7 | 63 | (41 -85) | |
| Disease phase | |||||
| Early | 285 | 93 | 65 | (59 -71) | .0001 |
| Advanced | 165 | 83 | 48 | (39 -56) | |
| Donor | |||||
| HLA-identical family | 306 | 103 | 65 | (59 -70) | .0003 |
| Other donors | 144 | 73 | 45 | (34 -55) | |
| Stem cell source | |||||
| Bone marrow + peripheral blood | 434 | 167 | 59 | (54 -64) | .1032 |
| Cord blood | 16 | 9 | 38 | (9 -66) | |
| GVHD prophylaxis | |||||
| Cs-A + MTX + ALG or mAb | 81 | 39 | 51 | (39 -62) | .0533 |
| Other prophylaxis | 369 | 167 | 61 | (55 -66) | |
| Conditioning regimen | |||||
| Chemotherapy based | 148 | 52 | 59 | (50 -69) | NS |
| TBI based | 302 | 124 | 58 | (52 -64) | |
| Acute GVHD | |||||
| 0-I | 223 | 89 | 58 | (51 -65) | NS |
| II-IV | 227 | 87 | 60 | (53 -67) | |
| cGVHD | |||||
| Absent | 308 | 134 | 55 | (49 -60) | .0013 |
| Present | 142 | 42 | 68 | (60 -76) | |
| cGVHD | |||||
| Absent | 308 | 134 | 55 | (49 -60) | .0055 |
| Limited | 89 | 26 | 68 | (58 -79) | |
| Extensive | 53 | 16 | 68 | (54 -81) | |
| . | Univariate analysis . | ||||
|---|---|---|---|---|---|
| No. of cases . | Events . | Probability, % . | (95% CI) . | P . | |
| Patient age | |||||
| Younger than 5 y | 110 | 35 | 66 | (56 -76) | NS |
| 5-10 y | 174 | 72 | 57 | (49 -64) | |
| 10-15 y | 125 | 52 | 57 | (48 -66) | |
| 15 y or older | 41 | 17 | 54 | (35 -72) | |
| Donor age | |||||
| Younger than 5 y | 81 | 31 | 61 | (50 -72) | .09 |
| 5-0 y | 95 | 31 | 65 | (55 -76) | |
| 10-15 y | 64 | 22 | 63 | (49 -76) | |
| 15-20 y | 55 | 18 | 65 | (52 -78) | |
| 20-30 y | 69 | 32 | 52 | (40 -64) | |
| 30-40 y | 56 | 24 | 48 | (34 -62) | |
| 40 y or older | 30 | 14 | 45 | (21 -70) | |
| Sex | |||||
| Female donor and male recipient | 103 | 53 | 59 | (50 -67) | NS |
| Other | 320 | 123 | 59 | (53 -65) | |
| Diagnosis | |||||
| ALL | 268 | 116 | 56 | (50 -62) | NS |
| AML | 99 | 30 | 64 | (53 -76) | |
| MDS | 36 | 15 | 54 | (35 -73) | |
| CML | 28 | 8 | 66 | (45 -87) | |
| Lymphoma | 19 | 7 | 63 | (41 -85) | |
| Disease phase | |||||
| Early | 285 | 93 | 65 | (59 -71) | .0001 |
| Advanced | 165 | 83 | 48 | (39 -56) | |
| Donor | |||||
| HLA-identical family | 306 | 103 | 65 | (59 -70) | .0003 |
| Other donors | 144 | 73 | 45 | (34 -55) | |
| Stem cell source | |||||
| Bone marrow + peripheral blood | 434 | 167 | 59 | (54 -64) | .1032 |
| Cord blood | 16 | 9 | 38 | (9 -66) | |
| GVHD prophylaxis | |||||
| Cs-A + MTX + ALG or mAb | 81 | 39 | 51 | (39 -62) | .0533 |
| Other prophylaxis | 369 | 167 | 61 | (55 -66) | |
| Conditioning regimen | |||||
| Chemotherapy based | 148 | 52 | 59 | (50 -69) | NS |
| TBI based | 302 | 124 | 58 | (52 -64) | |
| Acute GVHD | |||||
| 0-I | 223 | 89 | 58 | (51 -65) | NS |
| II-IV | 227 | 87 | 60 | (53 -67) | |
| cGVHD | |||||
| Absent | 308 | 134 | 55 | (49 -60) | .0013 |
| Present | 142 | 42 | 68 | (60 -76) | |
| cGVHD | |||||
| Absent | 308 | 134 | 55 | (49 -60) | .0055 |
| Limited | 89 | 26 | 68 | (58 -79) | |
| Extensive | 53 | 16 | 68 | (54 -81) | |